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 The production and distribution of counterfeit drugs is a critical health problem that 
plagues nations worldwide.  The presence of counterfeit antimalarials has become 
especially worrying, as these drugs are most often needed by those living in nations 
whose resources to verify the medicine supply are lacking.  Rapid analysis methods used 
for screening large quantities of poor quality antimalarials are critical in the battle to 
protect those in less developed regions of the world.  Simple, cost effective analysis 
methods that can be used in the field must be developed so those whose governments 
cannot afford to maintain medicine regulatory agencies can still have faith in their 
medicinal supply.   
 A very powerful screening method, Direct Analysis in Real Time Mass 
Spectrometry (DART-MS) has been used to investigate thousands of poor quality 
medicines.  This method, however, is known to fragment molecules more readily than 
commonly used, ‘softer’ ionization methods, such as electrospray ionization.  Excess 
fragmentation in ‘harder’ ionization sources is due to deposition of additional internal 
energy to the ionized molecules.  This internal energy deposition can be measured, so the 
analyst can be knowledgeable as to what to expect when examining unknowns using this 
recently developed ionization source. 
 Quantitation of the active pharmaceutical ingredient (API) in pharmaceuticals is 
crucial to the determination of what class a poor quality medicine fits into.  Because poor 
quality drugs can be of different types, it is important to accurately classify them, in 
hopes of improving the supply of medicines available to those in less developed regions 
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of the world.  High performance liquid chromatography (HPLC) is most commonly used 
to quantify the active pharmaceutical ingredient in poor quality medicines, however, this 
method is time consuming, preventing its use in high throughput settings.   
 During the course of my research, hundreds of poor quality pharmaceuticals were 
analyzed using DART-MS.  The active pharmaceutical ingredient was detected during 
the rapid screening for many of these drugs, however, a more in depth analysis would 
often reveal less than the expected quantity of active ingredient.  A rapid non-
chromatographic quantitation method was developed using a mass spectrometer as the 
detector.  This method allows for both quantitative and qualitative information regarding 
a specific sample to be obtained simultaneously, saving the analyst time and resources.  
Utilizing this non- chromatographic mass spectrometric method, degradation products 









Since the late 1990’s, detection of counterfeit antimalarial medicines, the most 
commonly used drugs in tropical regions, has been increasing1.  The World Health 
Organization (WHO) now recommends artemisinin-based combination therapies (ACTs) 
be used to treat malaria in most areas of Africa and South East Asia, where the multi-
drug resistant strain of malaria, Plasmodium falciparum malaria, is most commonly 
present2.  This treatment combines a short-lived artemisinin derivative and a longer-
lasting antimalarial, such as piperaquine or lumefantrine.  This new treatment has proved 
to be very effective against malaria, creating great hope. Unfortunately, ACTs are already 
being counterfeited worldwide due to their high demand and higher cost.  
Drugs can fall in one of four groups: genuine, degraded, substandard and 
counterfeit (fake).  A medicine is considered genuine when it contains the correct active 
pharmaceutical ingredient (API) in the correct amount, with the correct dissolution 
profile, and is contained in the correct packaging.  A medicine is classified as degraded 
when it is produced by the claimed legitimate manufacturers and known to have once 
contained the correct amount of active ingredient, but no longer present does so due to 
suboptimal storage conditions. Medicines classified as degraded can be verified as such 
through detection of API degradation products. A medicine is classified as substandard 
when it contains the correct packaging and can be traced to the manufacturer stated on 
the packaging, however, the drug was not correctly manufactured, possesses 
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unacceptable levels of impurities, exhibits incorrect dissolution properties, or the dosage 
of the active ingredient outside of the accepted range.  The final category of classification 
for medicines is counterfeit.  A drug is considered counterfeit when there is evident intent 
to deceive the customer: the packaging may be a copy, the expected API may not be 
present (or present in a trace amount), or an unexpected active ingredient not listed on the 




Figure 1: Images of genuine and counterfeit artesunate packaging holograms.  A genuine 
Guilin Pharmaceutical artesunate blister pack hologram can be seen in 1a, while 




Counterfeit drugs harm those taking them because these patients actually receive 
little to no effective treatment3, 4.  The presence of poor quality drugs also damages the 
pharmaceutical industry whose products are copied, causing billion-dollar losses. During 
my investigations of poor quality medicines, I have found that counterfeiters will go to 
great lengths to fool whatever regulatory agency (MRA) may be in place. In order to 
deceive the MRA or to cause a placebo effect, counterfeiters will often include different 
active ingredients than stated on the packaging (most common) or sub-therapeutic 
amounts of the stated active pharmaceutical ingredient in the counterfeit medicine. 
Infected people who take fake drugs that contain a lower dose of a therapeutic treatment 
are then effectively selecting parasites or bacteria that are resistant to this medicine.  This 
process could render some anti-infective drugs useless for the treatment of a particular 
strain of the infectious agent.  This issue, together with lack of compliance by patients, 
has rendered many monotherapy treatments for diseases such as malaria, completely 
ineffective.  Examples include mefloquine around the border of Thailand5, chloroquine in 
many regions of Africa and Southeast Asia6, and more recently reports have been made 
in Southeast Asia of resistance to artemisinin combination therapies7.  
The ability to quickly and easily identify poor quality medicines is a critical 
component of drug quality assurance.  Many techniques are currently used to establish 
medicine quality.  However, most of these require technologies that are not available in 
the countries that need them.  The countries where poor quality drugs are most prevalent 
tend to be less developed and have less resources, so many times these countries cannot 
afford to put a medicine regulatory agency in place to assure the quality of drugs 
available in that country.  Access to an affordable medicine quality control laboratory 
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(MQCL) is therefore essential.  The WHO encourages members to maintain such a 
laboratory2, but unfortunately this is not always possible due to lack of economic 
resources.   
Visual and physical inspection is the simplest of the techniques used to identify 
poor quality medicines.  Manufacturers do their best to employ anti-counterfeiting 
measures, such as unique holograms on the packaging as well as invisible covert features 
to ensure the authenticity of their products.  Unfortunately, with every development, it 
seems the counterfeiters are only one step behind.  The holograms adhered to packages of 
artesunate manufactured by Guilin Pharmaceutical Co. Ltd. have been extensively 
counterfeited.  Thus far, 16 different counterfeits have been indentified8.  Visual 
inspection of packaging involves inspection of the batch number, expiration date, and a 
close look at any insert that may be provided with the medicine.  The tablet is examined 
for size, markings, color, and chipped edges, indicators that the medicine being examined 
is not good quality.  In order to be absolutely sure that the packaging is not counterfeit, it 
is important to compare these packages with known genuine packages from all 
manufacturing plants for the medicine being inspected.   
Collaborators have used pollen analysis to determine the region of origin for 
drugs verified as counterfeit by other analytical methods9.  This method involves an 
analyst looking closely at the pollen under a microscope and possibly using an imaging 
technique to determine the type of pollen, if a grain is detected.  The types and amounts 
of different pollen grains found can narrow down the regions where these counterfeit 
drugs are being manufactured, assisting officials in stopping these harmful medicines 
from being traded.   
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Thin layer chromatography (TLC) is a simple and inexpensive tool that can be 
very effective in identifying poor quality medicines.  TLC plates and a variety of 
chemical reagents are necessary, along with minimal training for the person performing 
the experiment.  A genuine medicine from the same manufacturer is also required in 
order confirm results of the TLC experiment.  TLC is useful as a pass/fail mechanism, 
but cannot distinguish between the types of poor quality medicines.  A method has been 
reported which utilizes TLC and 2,4-dinitrophenylhydrazine or 4-benzoylamino-2,5-
dimethoxybenzenediasonium chloride hemi (zinc chloride) salt as the reagents, resulting 
in pink or blue products, respectively, only if a derivative of artemisinin is present10. 
As discussed previously, many developing countries do not have the technical, 
financial, or human resources required to inspect and police the drug supply.  Simple and 
affordable field methods, therefore, provide a practical means of rapidly monitoring drug 
quality.  Portable laboratories provide a versatile means of initial screening of most 
antimalarial formulations.  The GPHF MiniLab, a field laboratory compiled specifically 
for the analysis of antimalarials, uses a four-stage process to examine the quality of 
drugs: Visual inspection of solid dosage forms and packages, tablet and capsule 
disintegration test for a preliminary assessment of drug solubility, simple color reactions 
to identify drugs, and semi-quantitative TLC to check for quantities of API present, 
which requires the user to be trained prior to utilizing the MiniLab.  The Tanzanian Food 
and Drugs Authority piloted the use of the MiniLab kits and found it to be relatively 
inexpensive and rapid, but only grossly substandard or counterfeited samples could be 
distinguished.  While the MiniLab is a useful tool, it is recommended that it be used to 
complement drug analysis completed by a MQCL11. 
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High Performance Liquid Chromatography (HPLC) is the standard in determining 
quantity of active pharmaceutical ingredient present in medicines.  HPLC, which 
separates compounds based on their polarity or size, is a more complicated technique 
than the analytical methods used in the MiniLab and must therefore be performed in an 
MQCL.  Based on the retention time and area of the analyte peak, HPLC identifies and 
quantifies active pharmaceutical ingredients present in a drug, but requires a clean 
laboratory for sample preparation and many high purity solvents for analysis.  
Additionally, a standard is necessary to verify the identification of a particular drug when 
using HPLC to match retention times.  Between instrumentation and necessary 
consumables, HPLC is a quite costly analysis method, which results in this technique not 
being widely available in the poorest countries of the developing world.  . 
HPLC instruments can be coupled with many types of detectors.  Most 
commonly, UV/Visible absorbance detector, though other options include single 
wavelength, fluorescence, photo diode array, electrochemical, refractive index, or mass 
spectrometry detectors. Liquid chromatography-mass spectrometry (LC-MS) enables 
abundant chemical information to be obtained from each sample analysis, however, this 
technique relies on tedious, time-consuming sample preparation and requires a great deal 
of analysis time. 
Mass spectrometric analysis of poor quality drugs provides the analyst with 
qualitative information on every compound that is ionized in the medicine.  Because of 
this ability to detect the majority of ionizable compounds present, mass spectrometric 
analysis has the ability to distinguish between counterfeit, degraded, and substandard 
medicine, thought this analysis and classification is usually done in conjunction with 
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other analytical techniques.  For the screening of suspect poor quality medicines, Direct 
Analysis in Real Time (DART) is commonly used as the ionization source, as it allows 
for rapid analysis and does not require any type of sample preparation.  Desorption 
Electrospray Ionization (DESI) is an ionization technique that is also often used in the 
analysis of poor quality medicines.  DESI utilizes an ESI needle directed at a stage where 
the sample is placed12.  The charged solvent dissolves a small portion of the tablet and is 
sucked into the mass spectrometer inlet through an extended capillary.  This ionization 
technique, like DART, takes place in open air and requires no sample preparation, 
resulting in very high sample.  Despite the usefulness of mass spectrometry as an 
analytical technique, instrumentation and consumables necessary for analysis make it 
very costly and the analyst must have extensive training.   
 Inexpensive hand-held LED photometers are useful in measuring the absorbance 
associated with colorimetric reactions specific for active ingredients in pharmaceutical 
preparations.  Colorimetric methods have been published for many antimalarials, 
including artemisinin derivatives10, 13-15. Simple refractometers have also proven very 
useful in measuring dissolved active pharmaceutical ingredients in appropriate solvents15.  
Other inexpensive and portable instruments are useful in measuring physicochemical 
characteristics such as pH, tablet weight, viscosity of syrups, and density of suspensions 
and solutions.  The pH of a genuine artesunate tablet, for example, in aqueous alcohol is 
approximately 3.5, whereas some tested poor quality medicines had a pH of 
approximately 6.5.  Tablet weight of a particular class of counterfeited Guilin artesunate 
tablet tends to be approximately 10% more than then genuine tablet4.  While these 
portable instruments can provide the analyst with useful information, analysis should 
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always be run in conjunction a MQCL, to ensure accurate classification of poor quality 
medicines.   
 Nondestructive portable spectroscopic technologies are available for field-testing of 
poor quality medicines.  Infrared spectroscopy and Raman spectroscopy are currently 
being evaluated for rapid detection of poor quality medicines.  With these techniques, 
drug samples may be scanned through the plastic of the blisterpack while still in its 
original packaging and no toxic chemicals or flammable solvents are necessary.  Raman 
spectroscopy is based on the Raman effect, the scattering of light interacting with the 
different vibrational modes of the drug and excipient molecules contained in the tablet.  
One potential drawback of using Raman spectroscopy is that only the sample surface is 
probed, so if the active pharmaceutical ingredient is not distributed homogeneously 
throughout the entire tablet, the resulting content information may be inaccurate.  The 
spectra obtained using Raman spectroscopy cannot be deconvoluted into specific signals 
from different chemicals as it presents information regarding the functional groups in a 
molecule. In order to identify genuine samples, a fingerprinting method is used where a 
Raman spectrum is compared against a spectral database. It is also important to ensure 
that interference from an excipient does not cause the sample to be wrongly characterized 
as a fake.  Because of this, it is crucial to have a database of every genuine formulation 
from every manufacturer, thus decreasing the risk of incorrectly identifying a genuine 
drug as a poor quality medicine.  A common disadvantage seen when Raman has been 
tested to analyze pharmaceutical preparations is that many drugs contain highly 
fluorescent excipients, thus negatively affecting the quality of the spectrum.  
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Nevertheless, Raman spectroscopy has been successfully tested in the field for detection 
of counterfeits16.   
 Infrared spectroscopy utilizes the fact that different drug molecules absorb 
differently when excited with infrared light.  Unlike Raman spectroscopy, infrared 
radiation has a larger penetration depth, with the potential advantage being that the larger 
area examined can detect an active ingredient that is not perfectly homogeneous 
throughout the entire tablet. Infrared spectroscopy, like Raman, uses the fingerprinting 
method in order to match the sample spectrum to a compound in the database. Near-
infrared spectroscopy uses the near-infrared region of the electromagnetic spectrum (from 
approximately 800–2500 nm) and entails exciting the molecules in a sample and 
recording the unique fingerprint obtained. The method has been used to analyze 
excipients and may be used to demonstrate that they are not in the correct proportion, 
thus suggesting that the medicine is counterfeit17. 
 X-ray fluorescence (XRF) is a nondestructive technique that utilizes X-rays to 
determine which chemical elements are contained in a sample. When X-ray fluorescence 
is used for analysis, X-rays bombard the sample and characteristic emissions result from 
different elements.  This technique requires no sample preparation and is most commonly 
used for elemental analysis and to detect metals present.  Although the active 
pharmaceutical ingredient is not measured directly, the elemental composition of 
counterfeit drugs tends to be quite different from that of the genuine.  XRF, like Raman 
and infrared methods, requires a genuine tablet to verify whether a medicine can be 
classified as genuine or poor quality.   
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X-ray diffraction (XRD) is based on the elastic scattering of X-rays by the 
crystalline structures organized and aligned in crystals.  Powder diffraction is often used 
in identifying unknown samples.  This technique compares the spectrum obtained from a 
specific sample to a database containing spectra from every expected possibility.  This 
method is destructive, as the tablet must be crushed into a powder.  This method can also 
be used to measure the relative abundance of the major components in the sample, and 
usually provides information regarding excipients that is not easily obtained by mass 
spectrometry and other common analytical methods18.   
Many of the methods stated previously are used on a regular basis by CODFIN 
for analysis of poor quality medicines.  The analytical workflow currently in use by 
CODFIN to test samples collected in country-level drug quality surveys can be seen in 
Figure 2, below. Steps colored with light green background can be performed in the field 









There are increasing reports of poor quality antimalarials in Africa19. Since 1999 
there have been reports of counterfeit artesunate tablets from Nigeria, Chad, the 
Democratic Republic of the Congo (DRC) and Cameroon, counterfeit dihydroartemisinin 
tablets from Tanzania, Nigeria, Kenya and the DRC, counterfeit artemether tablets from 
DRC, substandard artesunate from Kenya, Ghana and Burkina Faso, poor quality 
artesunate tablets from Ghana, Nigeria, Tanzania and Uganda, poor quality artemether 
tablets from Kenya and Uganda and poor quality dihydroartemisinin tablets from Ghana, 
Kenya, Nigeria and Tanzania3, 20-26.  Monotherapy formulations, however, even when of 
good quality, should no longer be generally available27 and are being replaced by ACTs.  
Although, poor quality ACTs have yet to be reported in Asia there is an alarming increase 
of reported poor quality ACTs in Africa, e.g. artemether- lumefantrine tablets from 
Ghana, Nigeria and Uganda26, counterfeit artemether- lumefantrine from Ghana and 
Nigeria28-31 and counterfeit dihydroartemisinin- piperaquine from Kenya20.  In response 
to this apparent epidemic of poor-quality ACTs in Africa, we offered to analyze 
antimalarial medicines of suspicious quality in sub-Saharan Africa via meetings, word of 
mouth, INTERPOL and the Counterfeit Drug Forensic Investigation Network (CODFIN; 
www.codfin.org).  The study referred to reports these findings and assesses their 
implications for malaria control in Africa (See Appendix A.1). 
DART is an ionization technique often used in combination with mass 
spectrometry.  This ionization source is optimal for the screening of poor quality 
medicines, as it requires no sample preparation and has very high throughput.  This ion 
generation technology, first reported in 2005 by Cody et al., is becoming one of the most 
popular surface analysis methodologies amenable to open air operation (Figure 3). DART 
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utilizes a heated helium metastable plasma produced by a point-to-plane atmospheric 
pressure glow discharge.  Most often, helium is used as the discharge gas, though 
nitrogen can be used as the discharge gas as well.  The discharge gas molecules are 
subject to an electrical potential of around 3600 V, generating a glow discharge 
containing ionized gas, electrons, and metastable species (atoms in an excited state).  
These metastables are heated and directed through a grid electrode that prevents ion-ion 
and ion-electron recombination of ionic species generated within the DART ionization 
source. The most prevalent mechanism proposed for the formation of positive ions by 
DART involves Penning ionization of atmospheric water molecules induced by collisions 
with electronically-excited metastable helium atoms (He* 3S1, 19.8 eV) (Eq. 1)32: 
 He* g +nH!O(g)⟶He(g)+(!!O)!!!!!(g)+O!!(g)  (Eq. 1) 
Protonated water clusters of different sizes react with thermally-desorbed molecules (AB) 
(Eq. 2a) to undergo proton transfer to different extents depending on n (Eq. 2b)33.  
 AB(s)
heat





-­‐(n-­‐2)H2O ABH+(g) (Eq. 2b)  
Another ionization mechanism that has been observed under high grid voltages, 
small DART to mass inlet spacing, and low humidity conditions is direct Penning 
ionization of desorbed analytes34. This mechanism produces electron ionization-like 
spectra (Eq. 3) for low polarity compounds with low proton affinities. Under these 
conditions, charge exchange reactions with diatomic oxygen molecular ions can also 
occur (Eq. 4a and 4b)34. 





 He* g +O2 g ⟶He g +O2+ g +e-­‐ (Eq. 4a) 
 
 O2+ g +AB g ⟶O2 g +AB+(g) (Eq. 4b) 
 
These ionization processes occur in the sampling region between the DART ionization 
source and the mass spectrometer inlet.  Placement of a solid, liquid or gaseous sample in 
this region causes molecules on the sample surface to be desorbed as a result of the high 
temperatures and interaction with metastables, after which, reaction with water clusters 
occurs, resulting in a singly charged ion that is analyzed by the mass spectrometer. 
Although many applications of DART MS have been demonstrated in the 
literature35-37, this technique has not yet reached maturity. Many compounds exist that 
will not be readily ionized by DART.  For example, if a molecule is very large, heat alone 
may not provide enough energy to desorb a sufficient number of molecules into the gas 
phase to be detectable.  Also, in a case where a target compound does not have a higher 
proton affinity than water, analyte ions may not be formed when DART is run in the 
more commonly used positive mode.  Another stumbling block in the path of more 
efficient DART ionization is the choice of discharge gas used.  When nitrogen is used 
instead of helium, differences in excitation energies and heat conductivity cause a marked 
difference in sensitivity.  This phenomenon demonstrates that nitrogen excited states are 
lower in energy than most commonly populated electronic levels in metastable helium 
atoms, and that sample heating is much slower when nitrogen is used, limiting the 





Figure 3: Schematic of a DART ionization source. 
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The focus of this research was applying DART to the field of counterfeit drug 
detection.  One outcome of this research is the first database consolidating chemical 
analysis results from fake drugs collected in developing countries.  Hundreds of 
suspicious pharmaceuticals were analyzed using high-resolution DART time-of-flight 
(TOF) mass spectrometry and accurate mass measurements to identify their ingredients 
(See Appendix A.2). This work was carried out as part of the Bill and Melinda Gates 
Foundation (BMGF)-funded ACT consortium led by the London School of Hygiene and 
Tropical Medicine (LSHTM).  DART ionization is optimal for screening of suspect poor 
quality medicines because there is no need for sample preparation and each sample 
requires only seconds of analysis time.  Although the benefits of DART ionization 
outweigh the negatives for the screening of drugs, DART is a technique that causes more 
fragmentation to analytes than softer ‘soft’ techniques, like electrospray ionization.  The 
extent of fragmentation of a compound during ionization is directly proportional to the 
internal energy deposited to this analyte.  Internal energy deposition in DART becomes 
extremely relevant when applying it to the investigation of samples of unknown content. 
If several signals are detected in a mass spectrum due to fragmentation, the analyst may 
be tricked into considering each of them as individual sample components, severely 
complicating data analysis and possibly the experimental results.  Because analytes of 
interest are being unintentionally fragmented when a ‘hard’ ion generation technique is 
used, the intensity of the target peak is decreased, resulting in decreased sensitivity for 
the analyte of interest. 
When choosing an ionization method, the optimal situation would be one in 
which ionization causes no fragmentation unless the user chooses to purposely do so, for 
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example in a controlled tandem MS experiment.  The higher the internal energy 
deposition associated with a particular ion generation technology is, the more in-source 
induced fragmentation will be observed, resulting in a more complicated mass spectrum 
with lower sensitivity. 
 The extent of internal energy deposition can be determined by several methods38-
40.  The “survival yield method” was chosen for this study.  In this method, a series of p-
substituted benzylpyridinium salts whose dissociation energies are well known is used to 
probe the extent of internal energy in the system (Figure 4).  When these analytes are 
subject to DART, the energy imparted during ionization causes a certain degree of 
fragmentation. The intensity of the precursor ion peak is compared to the intensity of the 
product fragment ion peak; the ratio is converted to a survival yield.  By comparing the 
survival yields of the ions in the benzylpyridinium series to their known dissociation 
energies, the internal energy distribution produced by DART under various conditions 












To date, the majority of internal energy (Eint) deposition studies have focused 
primarily on spray-38-40 and laser-41, 42 based desorption/ionization techniques. Eint 
deposition studies of ions generated by atmospheric pressure chemical ionization (APCI) 
have focused on post-source Eint contributions to fragmentation43, 44 or isomerization45 
during in-source and tandem MS collision induced dissociation (CID). Previously, the 
Eint deposition of desorption electrospray ionization (DESI) has been investigated 
yielding insight on ion formation and energetics of this ambient ionization technique40.  
One of the most difficult tasks in screening of poor quality drugs is determining 
whether a drug fits into the classification defined as substandard or degraded.  In both 
classes, a lower than expected quantity of API is found.  The ability to distinguish 
between these classes, however, is crucial, as the solutions to these problems are very 
different.  If the poor quality medicines are substandard, the problem must be presented 
to the manufacturers, as the error is occurring during the production of the medicine.  
Degraded drugs, however, are caused by poor storage conditions, so the problem must be 
addressed with the pharmacies and other distributors.   
The ACT Consortium has begun a multi-year stability study to examine the 
stability of many ACTs under tropical conditions and to identify their degradation 
products.  In addition, many of these medicines are not stored as directed by the 
manufacturer.  Thus, many of these drugs may be degrading prior to their distribution to 
patients.  This is especially likely in countries with weak or no medicine regulatory 
agencies (MRAs).  The sheer number of samples involved in the ACT Consortium study 
implies that analysis by HPLC will require years of instrument time.  To obtain 
quantitative data without HPLC analysis, a rapid quantitative method utilizing mass 
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spectrometry was developed.  This method utilizes a gradient ratio standard addition 
approach.   
The gradient ratio standard addition method was initially developed as a 
calibration method for flame atomic absorption spectrometry46.  It was applied first to 
Flame Atomic Absorption Spectrometry (AAS), for detecting calcium in the presence of 
severe matrix effects.  This method has not been applied outside the field of atomic 
absorption spectrometry until now, despite its potential usefulness.  The gradient ratio 
standard addition method consists of consecutive injections, the first with analyte 
concentration Cs, and the second composed of the sample and the standard, with total 
analyte concentration Cs+r=Cs+Cr, where Cr is analyte concentration in the added standard 
alone.  Two traces are thus recorded: the sample trace with intensity vs. time Is, and the 
standard plus sample trace, with intensity Is+r.  These traces (chronograms) are overlaid 
and aligned so the initial edges match up.  Because the compounds that cause matrix 
effects are diluted as the peak decreases from the maximum to an intensity of zero but the 
ratio of the two traces remains constant, this method allows the analyst to treat the trailing 
part of the chronograms as a series of multiple standard additions with only a single 
physical addition of the standard. 
The ionization technique that was used for the flow injection gradient ratio 
standard addition method presented here is electrospray ionization (ESI).  ESI is a 
commonly used method of ionization in many applications.  During ESI, a solution is 
sprayed from a charged needle, leading to the formation of a Taylor cone47, 48.  The 
droplets being emitted from the cone break down due to Coulombic explosions and 
produce “naked” ions following, most likely, a combination of two proposed models.  
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The first is the ion evaporation model49, which suggests that as the charged droplet is 
decreasing in size due to collisions with the heated dry gas, the charge density on its 
surface becomes large enough to induce desorption of a charged analyte molecule.  The 
second model, known as the charged residue model50, proposes that electrospray droplets 






Figure 5: Schematic of electrospray ionization. 
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Although ESI has been used extensively for quantitation51 of APIs, quantitation 
can be done reliably only by using an internal standard52 to compensate for potential ion 
suppression effects, and by coupling to chromatography to simplify the resulting mass 
spectrum.  The optimal internal standard is a compound with the same ionization 
efficiency and a similar mass to the analyte.  The ionization efficiency will be similar for 
molecules with similar chemistries, thus the response by the mass spectrometer for these 
two compounds will be comparable.  The best internal standard is a stable isotope-labeled 
version of the analyte. Deuterated or 13C analogs, however, may be very expensive or 
may not be available at all.  The quantitative method presented here does not require such 
standards and avoids chromatography, thereby decreasing analysis time and increasing 
the number of samples that can be analyzed per hour. This method is well suited for 







2.1 DART Screening of Poor-Quality Medicines 
2.1.1 Solvents, Standards, Instrumentation 
 DART-MS was used to rapidly screen drugs for the expected active ingredient or 
any other compounds that may be present in drug samples. The DART 100 ion source 
was purchased from Ionsense (Saugus, MA, US). The mass spectrometers used for 
detection were a JMS-100TLC (AccuTOF) orthogonal acceleration time-of-flight mass 
spectrometer (JEOL USA, Peabody, MA, US) and a quadrupole time-of-flight hybrid 
instrument (Bruker MicroTOF Q I, Billerica, MA, US). Standards were purchased for 
artesunate (Apin Chemicals Ltd., Abingdon, Oxon, UK; Sigma, St. Louis, MO, US), 
dihydroartemisinin (Apin Chemicals Ltd., Abingdon, Oxon, UK), amodiaquine (Sigma, 
St. Louis, MO, US), pyrimethamine (Sigma, St. Louis, MO, US), mefloquine (Sigma, St. 
Louis, MO, US), quinine (Sigma, St. Louis, MO, US), chloroquine (Fluka, St. Louis, 
MO, US), sulfadiazine (Sigma, St. Louis, MO, US), and acetaminophen (Sigma, St. 
Louis, MO, US).  For calibration of the mass spectrometers, a 1.5 µM solution of PEG 
400 (Sigma-Aldrich, St. Louis, MO, US) in methanol (VWR, Radnor, PA, US) was used.  
The excitation gas used for all DART experiments was helium (Airgas, Atlanta, GA, 
US). 
 The DART settings used for analysis of suspect poor quality medicines were as 
follows: gas temperature of 200⁰C, grid 1 voltage of 50 V and grid 2 voltage of  150 V. 
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The discharge needle was set to 3600 V.  The flow rate of helium when the AccuTOF 
was used was most commonly 4 L min-1, while analysis on the MicroTOF Q required a 
lower flow rate of 1 L min-1.  When DART was used in conjunction with the MicroTOF 
Q, a Vapur® vacuum interface had to be employed to maintain the low pressure required 
by the instrument. This interface utilized a ceramic tube and aluminum vestibule 
connected to the mass spectrometer interface.  This vestibule was directly connected to a 
small diaphragm pump (Vacuubrand, Wertheim, Germany).  In this additional vacuum 
interface, neutrals are removed, and ions are guided into the mass spectrometer, resulting 
in the ability to use much lower gas flow rates while gaining sensitivity, as more of the 
ions in the ionization region are sampled into the mass spectrometer.   
 
2.1.2 Sample Collection 
 Collaborating members of the Counterfeit Drug Forensic Investigation Network 
(CODFIN) collected samples throughout Africa and South East Asia using both random 
and convenience sampling methods.  The most commonly used sampling method in 
studies of drug quality is convenience sampling.  Convenience sampling involves 
shoppers purchasing medicines without specific guidance as to which outlets to purchase 
medicines from.  Convenience sampling is a cheap, simple method that does not require a 
complete list of all outlets in the sampled region.  Compilation of such a list is most often 
a difficult task due to poor documentation in developing countries and unregistered or 
illegally run outlets.  Convenience sampling is very prone to bias, however, as the 
shopper may only purchase medicines from reputable outlets, poorly run outlets, or 
illegal outlets, depending on the outcome they prefer or expect.  As a result, convenience 
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sampling produces outcomes that may not accurately represent the true distribution of 
types of medicines in the region.   
 Random sampling results in a more accurate sampling of a region’s medicines.  
With a sufficient sample size, random sampling will result in reliable estimates of the 
prevalence of outlets providing poor quality medicines and their distributions in a defined 
geographical area.  This sampling method allows for comparisons to be made with 
subsequent estimates and allows for the evaluation of the effectiveness of any 
interventions taken to assist in solving the problems found.  The main drawback to the 
random sampling method is the fact that a very large sample size is required for accurate, 
usable data.  The costs associated with this large sample size can be quite high, a reason 
why many do not use this strategy.   
 Lot Quality Assurance Sampling (LQAS) method determines whether the 
prevalence of outlets selling poor quality medicines exceeds a certain threshold18.  This 
method is often used by companies to assure product quality.  LQAS helps keep the cost 
of determining the distribution of medicine types in a region low and it is often used as a 
precursor to the random sampling method.  Although this method is very useful, it also 
requires an accurate list of registered pharmaceutical distributors, which is difficult to 
attain. 
 
 2.1.3 Data Processing 
 Spectra resulting from DART screening of poor quality medicines are first 
examined for the drug stated on the packaging.  If there is no active ingredient specified 
or the packaging is not available, the spectra are examined for common antimalarials.  
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After this step, the (x, y) data is imported into an in-house developed database of many 
common drugs and excipients.  In most cases, the majority of intense peaks are identified 
as compounds in the database through their accurate masses.  If major peaks have not 
been identified at this point, SmartFormula, a software program provided by Bruker 
compares exact mass and isotopic ratios to determine the most likely candidates for the 
elemental formula of the selected peak.  To ensure the existence of a compound before 
that peak is labeled, ChemSpider, an online chemical database, is used to identify 
compounds with the elemental formula generated by SmartFormula.  In this way, the 
compounds contained in poor quality medicines are identified.   
 Once compounds are identified, all the MS, packaging and HPLC data is entered 
into a database that was created specifically for the compilation of all information on 
poor quality medicines.  Collaborators and MRAs can have immediate access to the data.  
See Appendix A.2 for more information on this database. 
 
2.2 DART-MS Internal Energy Deposition Studies  
2.2.1 Synthesis and Preparation of Para-Substituted Benzylpyridinium Salts 
The p-substituted methyl- (CH3), chloro- (Cl), cyano- (CN), and nitro (NO2) 
benzylpyridinium compounds were synthesized by condensation of the p-substituted 
benzyl halide with pyridine followed by recrystallization from diethyl ether as described 
by Katritzky et al.41.  Pyridine, nitromethane, anhydrous diethyl ether, anhydrous ethanol, 
and the benzyl halide starting reagents were all used without further purification (Sigma- 
Aldrich, St. Louis, MO, US). The methoxy- (OCH3) substituted compound was 
purchased (Arkat US, Inc. Gainesville, FL, US). All samples were stored in a -80 °C 
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freezer when not in use to minimize degradation. For DART experiments, an equimolar 
thermometer ion mixture (100 µM) was prepared in nanopure water (Barnstead 
International, Dubuque, IA, US), while for ESI experiments, a 1 µM mixture was 
prepared in either a nanopure water or a 50% methanol (Sigma-Aldrich, St. Louis, MO, 
US) solution. 
 
2.2.2 DART-TOF MS Sampling, Instrumentation, and Data Acquisition 
DART samples were prepared by pipetting 5 µL aliquots of the sample mixture 
onto the tips of DIP-it™ sample capillaries (IonSense, Inc. Saugus, MA, US) and 
allowing the drops to dry for 30 minutes. Sample deposition was repeated eight times so a 
total of 4 nanomoles of each compound was deposited on each capillary.  Capillaries 
were affixed to an in-house built sample holder attached to a hinged right-angle sample 
arm (Thorlabs, Newton, NJ, US) for reproducible sample placement during all 
experiments. 
MS analysis was performed with a commercial DART 100 ionization source 
(IonSense, Inc. Saugus, MA, US) and a JMS-100TLC (AccuTOF™) orthogonal 
acceleration time-of-flight (TOF) mass spectrometer (JEOL, USA, Peabody, MA). All 
experiments were performed in positive ion mode.  Ion optics and detector settings can be 
found in Appendix A.5.  A lower orifice 1 voltage was required for DART than for ESI, 
since it improved sensitivity. Preliminary experiments with DART at higher orifice 1 
voltages (40 V and 60 V) resulted in overall low sensitivity, with the higher Eo ions 





Figure 6: Sample placement for DART-TOF MS analysis of thermometer compounds. 
Samples were applied to Dip-it™ (diameter 0.16 cm) sample capillaries affixed to a 
stable sampling arm. Sample positioning distances: (i) center of MS orifice to capillary, 
0.60 cm, (ii) capillary depth below center of MS orifice, 0.16 cm, and (iii) capillary to 
center of gas outlet distance, 0.74 cm. 
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DART ion source settings were as follows: discharge needle voltage: 3600 V, 
discharge electrode voltage: 150 V, grid electrode voltage: 100 V, distance between ion 
source and spectrometer inlet: 1.5 cm, distance of sample capillary to MS orifice: 0.60 
cm, capillary depth below MS orifice: 0.16 cm, and capillary distance to the center of the 
DART gas nozzle: 0.74 cm (Figure 6). The rate of helium gas flow through the DART 
was 2, 4, or 6 L min-1, and the set heater temperature was 175, 250, or 325 ºC.  A solution 
of polyethylene glycol 600 (PEG, Sigma Aldrich, St. Louis, MO) prepared in 50% 
methanol was used as the mass calibration standard. A sample capillary dipped in the 
PEG solution was placed in front of the helium stream for 60 s, and a reference mass 
spectrum was obtained. Ultra high purity helium (99.999 %, Airgas, Atlanta, GA, US) 
was used in all DART experiments. Sample capillaries were held in the ionization region 
for 60 s.  Mass spectral data processing, calibration, and background subtraction were 
performed using the built-in mass spectrometer software (MassCenter, v. 1.3). The 
temperature at the tip of the DIP-it™ capillary was determined with an 80BK temperature 
probe connected to a digital multimeter (Fluke 179-True RMS, Everett, WA, US).  Ultra 
high purity nitrogen (99.995 %. Airgas, Atlanta, GA, US) was used following the exact 
procedure as helium experiments, but only the low dissociation energy compounds (p-
OCH3, p-CH3, and p-Cl) were detected in this case. This result made Eint calculations 
impossible due to the lack of data points on the fitted survival yield curves. The lower 
vibronic metastable energy level of nitrogen, and its lower thermal conductivity are 





2.2.3 ESI-TOF MS Experiments, Instrumentation, and Data Acquisition 
For ESI-TOF MS experiments, the DART ion source mounted onto the TOF mass 
spectrometer was replaced by the a pneumatically-assisted micro-ESI source (JEOL, 
USA, Peabody, MA). In this source, the nebulizing gas flows orthogonally (pointing 
downwards) to the mass spectrometer inlet orifice, while the drying (desolvating) gas is 
applied coaxially to the ESI needle assembly passing through a heated metal block to 
enhance desolvation. All mass spectrometer settings were identical to those used for 
DART-TOF MS experiments, with the exception that the orifice 1 voltage was set to 50 
V for ESI, the minimum setting that produced sufficient sensitivity. A 1 µM solution 
containing all five p-substituted benzylpyridinium compounds prepared in either 
nanopure water or 50% methanol was delivered to the ion source with a liquid handling 
pump (Valco Instruments Co., VICI M6, Houston, TX, US).  For the 50% methanol 
solution, the flow rate used was 200 µL min-1.  Due to the difficulty of desolvating 
aqueous droplets, however, a lower flow rate (150 µL min-1) was required to produce a 
stable spray from the aqueous solution.  A 1:10 000 dilution of the PEG solution was 
used as the mass calibration standard. Ion source settings were as follows: desolvation 
and nebulizing gas: nitrogen (99.995%, Airgas, Atlanta, GA), desolvation gas flow rate: 1 
L min-1, nebulizing gas flow rate: 2.5 L min-1, desolvating chamber temperature: 175, 
250, or 325 ºC, and needle voltage: 2500 V.  Mass spectral data acquisition, processing, 






2.2.4 Survival Yield Method and Data Analysis 
Uncontrolled ion activation within the ion source leads to an increase in the ions' 
Eint42.  Defined by Vékey as the “amount of energy an ion contains above the ground 
electronic, vibrational, and rotational states”43, Eint is a significant factor in determining 
ion fragmentation yields38.  Because of the heterogeneity of the processes occurring in 
atmospheric pressure and ambient ionization, the extent of ion activation is better 
described by P(E), the normalized probability distribution that an ion has a given Eint38,43.  
Many methods have been developed to determine P(E) including the “thermometer 
molecule” method53, the “deconvolution method”54, and the method used in this study, 
the “survival yield” (SY) method55, 56.  The SY method assumes that: (1) all ions with Eint 
below a critical energy, Eo, do not dissociate and appear as intact ionic species, and (2) all 
ions with Eint above Eo will dissociate into fragment ions38, 40.  Experiments are 
performed with a series of p-substituted benzylpyridinium salts with well characterized 
thermodynamic properties and a similar number of degrees of freedom.  The prevailing 
fragmentation pathway commonly observed for these salts is dissociation forming 
pyridine and a p-substituted benzyl cation at a known Eo.  Following ionization, the ratio 
of the precursor (Iprec) and fragment (Ifrag) ion intensities is calculated (Eq. 5)55, 56. 
    SYexp=
Iprec
Iprec+Ifrag
    (Eq. 5) 
SY values are then plotted against their respective Eo and two points 
corresponding to a SY value of 0 at 0 eV (indicating that no precursor ions would survive 
if the associated critical energy was 0 eV) and a SY value of 1 at 3.5 eV (indicating that 
at high critical energies, no fragment ions would be observed) are added in order to fit the 
data to a sigmoidal function (Eq. 6). 
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= ! ! !"!!    (Eq. 6) 
The SYFitted curve parameters, a, b, and x0, are experimentally fitted variables. The 
Eint distribution is determined by taking the first derivative of the sigmoid curve, 
generating the P(E) curve. The mean Eint, <Eo>, is then calculated by determining the 
centroid of P(E) (Eq. 7). 
          < !! >=
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    (Eq. 7) 
An example of experimental data fitted to the sigmoidal function, then integrated can be 
found below, in Figure 7.  For data analysis, each chronogram was averaged for one 
minute using the built-in mass spectrometer software (MassCenter, v. 1.3) and the 
spectrum was exported into Excel (Microsoft, Auburn, WA, US).  After manually 
selecting peak maxima for the ions of interest, and calculating survival yields of each 
(Eq. 1), the data were treated with an in-house programmed macros to fit the survival 
yields to a sigmoid curve and to calculate the residual error of the fit, Eint distribution, 





Figure 7: The upper panel represents the survival yield of each investigated 
benzylpyridinium ion versus its known critical energy is fit to a sigmoidal function using 
Equation 6.  Theoretical data points of (0,0) and (3.5,1) were added to fit the sigmoidal 
function to the data.  The lower panel represents the integral of the data fit in the top 
panel.  The peak of this integral is the average internal energy for these compounds under 
the conditions used for the experiment, in this case, the DART ionization source was set 
to a temperature of 175°C and the discharge gas was running at 2 L min-1. 
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2.3 Flow Injection Gradient Ratio Standard Addition Method for MS 
2.3.1 Solvents, Standards, Instrumentation 
 Artesunate, an important and widely used antimalarial medication, was used to 
develop the flow injection analysis technique.  In all experiments, artesunate was 
extracted directly from tablets, so any matrix effects due to tablet excipients were present 
in all experiments.   
In order to quantitatively measure the amount of artesunate, a tablet (Mekophar 
Chemical Pharmaceutical JSC, Vietnam; Holley-Cotec Pharmaceuticals Co., Ltd., China, 
Guilin Pharmaceutical Co., China) was first homogenized using a mortar and pestle.  The 
powder from the entire tablet was then placed in a vial and mixed with 10 mL of 
methanol (Sigma, St. Louis, MO, US).  The solution of artesunate and methanol (and 
excipients that may have been extracted with the artesunate) was kept on ice for the 
entirety of the extraction process and all experiments.  After being shaken every five 
minutes for a total of 40 minutes, the artesunate extract was filtered through a 0.45 µm 
PTFE membrane (MicroLiter Analytical Supplies, Inc., Suwanee, GA, US).  This extract 










2.3.2 Flow Injection Setup 
The workflow used for FI-GR-SA-MS is shown in Figure 8.  An HPLC pump 
(Agilent, Santa Clara, CA, US) delivering methanol at a rate of 150 µL min-1 was 
connected to the inlet of a software-controlled 6-way divert valve (Rheodyne (now IDEX 
Health and Science), Oak Harbor, WA, US), which was installed in the front panel of the 
mass spectrometer.  The exit duct of the divert valve was connected to the mass 
spectrometer inlet.  A syringe pump (Cole Parmer, Vernon Hills, IL, US) was used to 
load the sample into the loop of the divert valve in a reproducible manner.  The sample 
coil used in this case was made of PEEK tubing and had a volume of 7.5 µL.  
Approximately 250 µL of sample solution were used to flush the sample loop and avoid 
carryover from previous samples.  Six seconds into each MS run, the 6-way valve was 
switched, injecting the contents of the sample loop as a plug into the constant stream of 
methanol flowing into the electrospray ionization source.  Each FI-GR-SA-MS run 
required 30 seconds of mass spectrometer acquisition time. 
 
2.3.3 Mass Spectral Analysis 
Mass spectral analysis was performed using a Bruker MicroTOF Q mass 
spectrometer.  The settings were optimized for a mass-to-charge ratio of 570.4, the 
expected mass-to-charge ratio of the protonated artesunate/dodecylamine proton-bound 






2.3.4 Data Analysis 
Data was analyzed using the gradient ratio standard addition method.  Equations 8 
and 9, used for data analysis, were adapted from the work by Koscielniak46 and can be 
found below.   
    !!" =
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!!    (Eq. 8) 
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    (Eq. 9) 
Cap is the apparent concentration of the sample without standard added.  Is,t is the intensity 
of the sample signal at a certain point in time.  Is+r,t is the intensity of the sample plus 
standard at a certain point in time.  Cr is the concentration of the standard that was added 
to the sample.  The first equation uses these variables to calculate the apparent 
concentration, which is plotted against the relative dilution at each time point, k(t).  The 
relative dilution is calculated from Is+r(t), the intensity of the sample plus standard at a 
particular point, divided by Is+r(tmax), the intensity of the sample plus standard at the 
maximum.  The maximum of the sample plus standard trace is chosen as the first point 
for analysis and data is then analyzed point by point down to the 10% relative dilution 
value calculated with Equation 9.   
 
2.3.5 Degraded Samples 
 In order to search for artesunate degradation products, genuine samples that had 
not yet reached their expiration date were artificially degraded in an oven heated to 





2.3.6 HPLC Conditions 
 Samples were extracted in methanol and diluted to a theoretical concentration of 2 
mg/mL.  These extracts were run through a 0.45 µm nylon filter (MicroLiter Analytical 
Inc., Suwanee, GA, US), then placed in an HPLC vial (Agilent, Santa Clara, CA, US).  
The international pharmacopeia accepted method of artesunate analysis was the HPLC 
method followed.  A potassium phosphate buffer was prepared using potassium 
dihydrogen phosphate (Sigma, St. Louis, MO, US) and deionized water.  The buffer was 
adjusted to a pH of 3 using phosphoric acid (Sigma, St. Louis, MO, US).  This buffer was 
used in a 50:50 ratio with acetonitrile for the mobile phase.  A reverse phase C18 column 
(Supelco, St. Louis, MO, US) was used for analysis of the degraded artesunate.  An 
artesunate standard (Sigma, St. Louis, MO, US) was used to prepare calibration curves 
for HPLC experiments.  Calibrant solutions had concentrations of 1, 2 and 3 mg/ml.  The 
UV detector was set to a wavelength of 216 nm.  The mobile phase was flowed at 0.6 mL 







3.1 Screening of Poor Quality Medicines 
3.1.1 Survey of Poor Quality Artemisinin Combination Therapy and other Antimalarials 
in Africa 
 A large survey of drugs in Africa has been ongoing for the past five years.  
Hundreds of samples collected have been thoroughly analyzed in the context of this 
study.  Sadly, many counterfeits have been uncovered.  Figure 10 represents the results 
obtained for a study of drugs collected by INTERPOL.  A specific detected counterfeit, 
for example, was uncovered in the tablets coded GH 09/01 (see Appendix A.1, Figure 9), 
the active pharmaceutical ingredient stated on the packaging was a co-formulation of 
artemether and lumefantrine, as can be seen in Figure 9.  The upper panel of this figure 
displays the mass spectrum of the sample analyzed, while the lower panel is the mass 
spectrum of a genuine drug, with an zoomed inset of the peaks, revealing characteristic 
isotopic abundances of the genuine drugs.  When the sample was screened using DART-
MS, no artemether or lumefantrine was detected, however, pyrimethamine, another 
antimalarial was identified.  Because lumefantrine is a yellow drug, the co-formulation of 
lumefantrine and artemether is a yellow tablet.  The counterfeit tablet containing 
pyrimethamine appeared yellow, indicating the counterfeiters went to the trouble to 
camouflage the tablet in order to fool those they would sell the fake medicine to.  The 





Figure 9: Example of genuine and counterfeit mass spectra for GH 09/01, a sample 
stated to contain artemether (m/z 316) and lumefantrine (m/z 528).  Counterfeit contained 
pyrimethamine (m/z 249).  
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 In the case of the medicine coded 4024 Nigeria (see Appendix A.1), the 
blisterpack indicated the contents being the antimalarial halofantrine, a drug sold by 
SmithKline as ‘Halfan’.  When screened using DART-MS, it was discovered that this 
medicine did not contain halofantrine, but contained acetaminophen instead.  This type of 
formulation is especially dangerous because the infected patient will take the medicine, 
their fever will break, and they will begin to feel better.  Unfortunately, the medicine is 
not fighting the parasite, it is only masking the symptoms of malaria, so the person will 
believe they are getting better, but ultimately, their condition will not have been treated. 
 Poor quality medicines can show a wide array of compositions, which is why 
analysis by so many methods is crucial to ensure the quality of a drug supply.  In the case 
of the sample coded DRG 06/01 (Appendix A.1), when it was screened using MS and 
analyzed with HPLC, no active pharmaceutical ingredient was detected.  This sample was 
composed exclusively of excipients, making it obviously counterfeit.  In the case of 
sample UG 09/02, however, the expected active pharmaceutical ingredients were present 
in acceptable quantities and the majority of examined parameters appeared genuine, 
however no perforations were present across the blisterpack, which should be present in 
the genuine sample.  The lack of this small detail suggested that this medicine was 
counterfeit.  Samples like this demonstrate the lengths counterfeiters will go to for their 
medicines to appear genuine.   
 The most interesting samples examined in the course of this work were those 
coded CHINA 07/18- CHINA 07/21.  The packaging stated these to be a co-formulation 
of dihydroartemisinin and piperaquine.   When these medicines were analyzed by DESI-
MS, analysts were surprised to detect the presence of sildenafil, the active pharmaceutical 
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ingredient in Viagra® in these antimalarials.  The effect of this drug in patients with 
malaria is unknown, as sildenafil is most often taken by those who suffer from a very 
different ailment.  This unexpected active pharmaceutical ingredient could have grave 
repercussions, as those with hypertension are warned against ingesting sildenafil.  These 





Figure 10: Pie chart representing proportions of sample set in each of the medicine 











3.1.2 Randomized survey of antimalarial drug quality in Laos 
 Previous studies performed using convenience sampling in the Lao People’s 
Democratic Republic (Laos) indicated that between 38 and 54 percent of all oral 
artesunate tablets collected in a four year time frame (2000-2003) were counterfeit.  A 
follow-up study utilizing a random sampling method was carried out to verify this 
finding.  Outlets were randomly chosen based on a statistician’s random number tables 
from lists of provinces and districts within the selected sampling region.   
 One hundred and eighty outlets were sampled in the current study, representing 
33.9% (180/531) of all pharmacies and shops selling medicines recorded in the study 
areas and 8.1% of all licensed pharmacies in Laos in 2003 (163/2,014).  The majority of 
outlets sampled during the first collection were licensed pharmacies (81.5%).  Shops 
selling artesunate were found in 7/ 12 (58.3%) districts. All pharmacies were Class 3 (i.e. 
'with the licensee being neither pharmacist nor assistant pharmacist'.  Artesunate was 
found in 25 of all 180 outlets (13.9%).  Considering only the pharmacies, 15.3% (25/163) 
sold artesunate.  No artesunate was purchased from shops selling medicines. Only one 
brand of artesunate was found in each pharmacy. Five pharmacies (20%) offered two 
blisterpacks of artesunate and the remaining 20 offered one.   
 All samples were sold in blisterpacks. By inspection of packaging, without 
knowledge of the chemical results, 26/ 30 (87% (95%CI 68–96%)) artesunate samples 
were counterfeit, three were genuine (10%) and the classification of one sample (12 Pas 




 There was 100% agreement between the Fast Red dye test14, HPLC, and MS 
analysis for the 30 samples labeled as artesunate57. All those classified as counterfeit 
based on the packaging contained no detectable artesunate. Chemical analysis of the 
sample with insufficient packaging (mentioned above) was shown by MS to contain 
pyrimethamine, sulphadoxine, and paracetamol, but no artesunate and was, therefore, 
counterfeit. The combination of packaging and chemistry demonstrates that 27/30 (90%) 
(95%CI 72–97%) of artesunate samples were counterfeit. In terms of outlets, 22/25 
(88%) (95% CI 68–97%) sold fake artesunate. The three genuine samples contained a 
median (range) artesunate content/tablet of 49.2 (45.1– 50.3) mg (all had stated tablet 
content of 50 mg artesunate). The 27 counterfeit samples that underwent forensic MS 
analysis were found to contain paracetamol (16), sulphadoxine (12), dimethylfumarate 
(6), metamizole (5), pyrimethamine (8), erythromycin (5), artemisinin (4), 2- 
mercaptobenzothiazole (3), chloramphenicol (2), chloroquine (1) and erucamide (1). The 
concentrations of artemisinin as determined by HPLC were 0.26, 4.50, 6.50 and 115.7 
mg/tablet, chloroquine 14.7 mg/tablet, pyrimethamine 17.1, 16.0, 16.6 mg/tablet and 
sulphadoxine 409.6, 385.9, 413.9 mg/tablet. Of 12 and 8 samples found by MS to contain 
sulphadoxine and pyrimethamine, respectively, sulphadoxine and pyrimethamine were 
found by HPLC in only three and three samples, respectively. The ratios of 
pyrimethamine to sulphadoxine, normally 1:20 in sulphadoxine- pyrimethamine (SP) 
coformulated tablets, were 1:24.0, 1:24.1 and 1:24.9 – suggesting that the counterfeits 
may have been formulated from powder after the co-drugs had been mixed to 
manufacture SP tablets. Of 4 samples examined with XRD, calcite was detected in three 
and starch in one. The stable isotope analysis of the calcite suggested a high temperature 
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or volcanic origin. The results from the pollen analysis are consistent with a source of the 
fake artesunate in southern China, but do not prove this geographical origin. 
 
3.2 Internal Energy Deposition of DART-MS 
3.2.1 Determination of the Eint Deposition of DART Compared to ESI 
Various energy-depositing processes occur during DART ionization. For the 
thermometer compounds tested in this study, potential energy deposition pathways begin 
with the thermal desorption of the solid neutral salt into the gaseous phase (Scheme 1i). 
The neutral salt undergoes charge splitting to form the halide anion and the precursor 
cation via atmospheric pressure thermal desorption ionization (APTDI)58, and/or the 
effect of the electric field established between the needle electrode, grid electrode, and 
the mass spectrometer inlet orifice (Scheme 1ii). Further activation of the precursor 
cation proceeds through additional heating (Scheme 1iii), reactive collisions with 
metastable He species (He*) (Scheme 1iv), and/or deposition of excess energy released 





















































At the lowest assayed helium gas heater (DART) or desolvating chamber (ESI) 
temperature set point (175 ºC), both aqueous and 50% methanol solutions probed by ESI 
had lower <Eo> values (1.71 eV and 1.53 eV, respectively) compared to DART at all 
three gas flow rates tested (2 L min-1: 1.92 eV, 4 L min-1: 2.02 eV, and 6 L min-1: 2.08 
eV) (Figure 11a). In comparison to the softest ESI conditions with a 50% methanol 
solution, at 175 ºC, DART <Eo> values were higher by 25%, 32%, and 36% at 2, 4, and 6 
L min-1, respectively. The same trend followed at 250 ºC (Figure 11b), corresponding to 
DART <Eo> values that were higher than 50% methanol ESI values by 30%, 34%, and 
38% at 2, 4, and 6 L min-1, respectively. Furthermore, <Eo> values at 325 ºC for DART 
(2 L min-1: 2.09 eV, 4 L min-1: 2.18 eV, and 6 L min-1: 2.21 eV) were higher than the 
comparable experiments for the 50% methanol ESI values by 28%, 33%, and 35% at 2, 4, 
and 6 L min-1, respectively (Figure 11c).  The shape of the Eint distributions displayed no 
asymmetric tailing at all temperatures tested59.  These <Eo> values indicated that under 




Figure 11: Mean Eint (<Eo>) distributions for DART and ESI with helium gas heater 
(DART) or desolvation chamber (ESI) temperature set points of a) 175 ºC, b) 250 ºC, and 
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The aqueous solution analyzed by ESI had higher <Eo> values in comparison to 
the 50% methanol solutions by 12%, 13%, and 20% at 175, 250, and 325 ºC, 
respectively.  Due to the higher vapor pressure of methanol, droplets produced from a 
50% methanol solution desolvate faster than aqueous droplets and cool more rapidly. The 
differences in Eint deposition observed between ESI experiments were consistent with 
prior investigations showing that P(E) could be altered by varying the solvent system 
vapor pressure, greatly affecting thermal and kinetic energy contributions55.  Sprayed 
droplets acquire thermal energy by in-source heat conversion and friction with gas 
molecules to an extent that depends on droplet sizes40, 55, 60, 61.  Kinetic energy from 
electric field-driven acceleration of charged droplets and ions can also be deposited into 
Eint modes, both in the atmospheric pressure region and within the various reduced 
pressure regions of the mass spectrometer interface38, 40, 62.  
 
3.2.2 Thermal Activation Pathways 
 In ESI, heated gas serves the role of improving charged droplet desolvation before 
entering the ion transfer optics region48, 63.  This differs from the role of the heated gas 
used in DART experiments, which is to evaporate residual solvent and thermally desorb 
the analytes.  If set high enough, temperatures induce unwanted fragmentation of labile 
species.  It is quite important to distinguish between the DART temperature set by 
software, and the actual temperature within the ionization region.  Measured gas 
temperatures at the bottom of the sample capillaries rapidly decreased upon increasing 
the flow rate setting as a result of rapid convective cooling of the ionization source 
environment.  Direct temperature measurements (Figure 12) indicated that the actual gas 
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temperature was consistently lower than the set value, and that the difference between the 
two increased with increasing flow rates.  When the heater was set at 175 ºC (Figure 
12a), the average steady-state gas temperatures at 2, 4, and 6 L min-1 were 163 ºC, 145 
ºC, and 136 ºC, respectively.  This downward trend was the same for set temperatures of 
250 ºC (2 L min-1: 227 ºC, 4 L min-1: 200 ºC, and 6 L min-1: 187 ºC) (Figure 12b) and 325 




Figure 12: Measured gas temperature at the bottom of the sample capillary in the DART 
ionization region at experimental set temperatures of a) 175ºC, b) 250ºC, and c) 325ºC. 












































































The measured “effective” temperatures strongly influenced the extent of Eint 
deposition. Ions generated at a high flow rate (4 and 6 L min-1) at any set gas temperature 
were created in a thermally cooler environment compared to those created at low flow 
rates (2 L min-1).  Ion formation in a locally cooler environment is expected to lead to a 
decrease in thermal-induced fragmentation59, 64, 65.  Contour maps for the data in Figure 
11 were created to assist in understanding the Eint deposition trends observed 
experimentally (Figure 13).  The Eint contour map for ESI indicates a decrease in Eint 
deposition with increasing concentrations of methanol at lower temperatures (Figure 13) 
as previously reported in similar work55 and discussed above.  The DART map shows 
that the least amount of energy was deposited at lower gas flow rates and temperatures 
(blue to green on the color scale), whereas the highest energy deposition occurred at high 
flow rates and set temperatures (yellow to red color scale, Figure 13).  Because lower 
measured gas temperatures were detected at higher flow rates, thermal ion activation 
could not account for the increase in Eint observed under those conditions.  Although ESI 
is clearly a ‘cooler’ ionization source, there is some overlap between the internal energy 




Figure 13: Mean Eint surface contour maps for DART (upper plot) and ESI (lower plot). 
Temperatures plotted on the x-axis correspond to set points in the ion source control 
software. 
Set DART Temperature (C)

































































Figure 14: Observed absolute abundances of protonated water clusters with “n” water 
molecules ((H2O)nH+) at set DART temperatures of a) 175 °C, b) 250 °C, and c) 325 °C 
and different glow discharge gas flow rates. The electrical current on the discharge needle 




 Increase in <Eo> may also result from the excess energy released during 
dissociative proton transfer reactions with protonated water clusters (Scheme 1v)66.  An 
increase in the intensities of protonated water cluster ions when increasing the set gas 
temperature was observed at all flow rates (Figure 14).  At 175 °C (Figure 14a), 250 °C 
(Figure 14b), and 325 °C (Figure 14c), clusters with n ≤ 6 were the most abundant.  This 
suggests that the pathways shown in Scheme 1iii and 1v, may act concurrently. The 
abundance of clusters with n ≥ 8 was observed to increase at low flow rates. This is to be 
expected, due to the increased hydrate thermodynamic stability at higher temperatures67.  
The trend was less clear for smaller hydrates. As a whole, however, the increase observed 
in protonated water cluster intensities as flow rate was decreased did not explain the 
changes in internal energy deposition.  This suggests that additional collisional activation 
during transit through the ion optics or other pathways, such as that shown in Scheme 
1iv, may play a significant role in further determining <Eo>.  This alternative activation 
pathway involves direct Penning ionization of thermometer ions with He* producing 
pyridine molecular ions (Py+.). This ionization pathway is not expected to be prevalent at 
low exit grid voltages and high ambient humidity (45%)64.  When DART mass spectra 
were examined in detail, Py+. was detected in low abundance.  As expected, protonation 
of the pyridine molecule was favored significantly over the formation of Py+. at all tested 
flow rates and temperatures with a net increase in Py+. abundance at higher effective 
temperatures. The relatively low abundance of Py+. (0.61 % on average) suggests that 
under the present conditions, the pathway depicted in Scheme 1iv should not be 




3.2.3 Collisional Activation Effects. 
 In-source collision-induced dissociation (CID) is generally performed by 
increasing the acceleration voltages applied to orifices and skimmers in the first stage of a 
differentially-pumped mass spectrometric system.  Higher potential differences in the 
first differentially pumped regions produce more energetic collisions with gaseous 
molecules, inducing higher fragmentation yields during ion transport towards the mass 
analyzer.  In-source CID yields can also be influenced by the gas pressure in the 
spectrometer’s interface67.  As pressure (P) in this region increases, the mean free path (λ) 
decreases (λ α 1/P) leading to a decrease in the collisional energy transfer68.  Ultimately, 
this manifests into a reduction in ion fragmentation and a decrease in the Eint deposition59.  
To investigate the existence of this type of effect, the pressure of the first differentially-
pumped region was monitored via a Pirani gauge for all DART and ESI experiments 




Table 1: Pirani gauge pressure for first TOF differentially-pumped chamber under 
various experimental DART and ESI conditions. 
 
 
*Pressure values listed here were constant for all experiments 
 Temperature Set 
Points 175 ºC 250 ºC 325 ºC 
DART: 2 L min-1 260 Pa 240 Pa 230 Pa 
DART: 4 L min-1 240 Pa 230 Pa 200 Pa 
DART: 6 L min-1 230 Pa 220 Pa 190 Pa 
ESI: Aqueous blank 210 Pa 210 Pa 210 Pa 
ESI: 50% methanol 
blank 210 Pa 210 Pa 210 Pa 
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A decrease in pressure was observed when both the DART ion source temperature 
and flow rate settings were increased. No changes were observed for ESI.  It is thus 
highly likely that the increase in pressure in the first differentially pumped region as the 
DART gas flow rates were decreased is responsible for the lower Eint deposition observed 
a given set DART gas temperature.  
 
3.2.4 Influence of Fluid Dynamics on Eint Deposition. 
 Previous ESI energy deposition studies have shown a correlation between the ion 
source design, and the mean value and width of the Eint distribution55. Using the DART 
ion source, design, and experimental variables such as sample positioning, gas 
temperature, and gas flow rates determine neutral and charged particle trajectories within 
the ionization region. Previous studies from our group have suggested that particle 
circulation may occur in some sampling geometries, decreasing experimental 
sensitivity33. In the present context, particle circulation may also lead to longer residence 
times in elevated temperature regions and/or cause more collisions with energetic 
metastables, reactive ions, and neutral molecules. 
 
3.2.5 Metastable-stimulated Desorption Effects 
 Cody et al. have suggested that desorption in DART may include both thermal 
and non-thermal processes, such as bombardment of the sample surface by metastables or 
ions32. According to the results presented thus far, the former can be considered as being 
a predominant pathway for energy deposition. Example of the latter include reactive 
chemical sputtering69, and metastable-stimulated desorption (MSD). In MSD metastable 
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rare gas atoms are directed at a surface in-vacuo and collide with the outermost surface of 
the sample, creating an electron hole via Auger de-excitation of the metastable species70, 
71.  This process can create a repulsive potential between the surface and analyte 
stimulating desorption.  To investigate the presence of these non-thermal desorption 
processes, survival yield experiments were attempted using unheated helium metastables.  
Benzylpyridinium ions were not detected from either slurries, liquid solutions, or from 
completely dried salts under any of the conditions previously tested suggesting the 
absence of Eint deposition pathways involving non-thermal desorption processes. 
 
3.3 Flow Injection Gradient Ratio Standard Addition Method for MS 
3.3.1	  Analysis of	  Artesunate-Dodecylamine Complexes by MS 
Dodecylamine (DDA) was added in excess to sample solutions of artesunate prior 
to FI-GR-SA-MS analysis.  DDA forms a proton-bound non-covalent complex with 
artesunate, resulting in a higher intensity ESI signal than that from a pure artesunate 
solution.  The amine forms a complex by hydrogen bonding between the amine nitrogen 
and the ether like moieties in the artesunate lactone ring.  The gain in ESI signal is due to 
the localization of the positive charge of the complex at the nitrogen atom of the 
dodecylamine72.  Also, the addition of a positively charged hydrophobic ligand to the 
artesunate molecule enhances ion evaporation upon exiting the ESI needle.  The result is 
a complex with higher ionization efficiency that also assists in impeding fragmentation of 




Figure 15: Representative mass spectra of artesunate with (a) and without (b) DDA 
added to the solution.  The m/z of artesunate [M+Na]+ is 407.2, as can be seen in panel b, 
while the m/z of the [artesunate+DDA+H]+ complex is 570.4, as seen in panel a.  Note 





Figure 15 demonstrates the difference in signal when DDA is used as opposed to 
pure artesunate for FI-GR-SA-MS analysis.  While the spectra with DDA appear much 
more complex due primarily to additional DDA species in the spectrum, the intensity of 
the signal for the artesunate-DDA complex is increased.  In this case, distinguishing new 
peaks due to degradation products or contaminants in the artesunate tablet may be more 
difficult, especially if the degradation product or contaminant is present at very low 
concentration or is not preferentially ionized.   
 
3.3.2 Matrix Effects 
 Although this method only requires a single point standard addition, the point by 
point analysis of the trailing dilution tail of the FIA peak results in a method that can still 
accurately account for matrix effects.  Analysis of the extracted ion chronogram (EIC) 
traces results in multiple reproducible dilution ratios.  Because any matrix that may be 
interacting with the analyte of interest is diluted as the peak decreases from the 
maximum, the effects of that matrix are also decreased as the solution is diluted.  In this 
trailing portion of the signal, not only the matrix present is diluted, but the intensity of all 
ionic species of interest is decreasing as well, however, the ratio of the sample and 
sample plus standard traces converges to the correct apparent concentration, as 
demonstrated below.  
 
3.3.3 Method Performance 
 The FI-GR-SA-MS method was analyzed for figures of merit that are most 
commonly evaluated in new analytical techniques.  First, the linear range was evaluated. 
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This is an important parameter, as it limits the concentration interval that can be reliably 





Figure 16: Electrospray response of the [artesunate+DDA+H]+ complex.  Experiments 

















Linear Range for Protonated Artesunate+DDA peak
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 The upper limit of the linear range for these experiments was approximately 2 
µM, with a lower detection limit in the 30 nM range.  To match the linear response range, 
unknown or degraded solutions were most often diluted to a theoretical concentration of 
1 µM for all experiments, to ensure that the upper linear limit was not reached.  This 
linear limit was determined using the artesunate+DDA complex.  The linear limit for 
when the sodiated artesunate ion is used may differ significantly. 
 Initial investigations on the accuracy of the FI-GR-SA-MS method are shown in 
Figure 17.  All standards prepared had a concentration below 2.5 µM to avoid exceeding 
the linear range.  The x-axis represents the theoretical concentration of artesunate in the 
prepared unknown solutions, while the y-axis represents the concentration of the sample 
solution measured using the FI-GR-SA-MS method.  If this method is accurate, the 
equation of the line fitting the theoretical concentration of the solutions versus the 
measured FIA concentrations in this plot should have a slope of one and a y-intercept of 
zero.  The confidence intervals for the regression parameters were calculated at the 95% 
confidence level, showing that this technique is accurate within the experimental 
variance, and suggesting that it can accurately detect the concentration of artesunate in 




Figure 17: Accuracy of FI-GR-SA-MS analysis estimated by comparing measured 
concentrations to concentrations of synthetic unknown standards. Experiments were run 




3.3.4 Identification of Degradation Products 
 Degradation products are formed in artesunate tablets as a result of exposure to 
high temperatures and/or high humidity conditions for extended periods of time.  Because 
degradation products of artesunate have only been studied in suppositories73, 
identification of artesunate degradation products in tablets was undertaken.  A study was 
designed to progressively degrade artesunate tablets and investigate which products are 
produced using MS.  First, genuine artesunate tablets were manually degraded in an oven 
at 100⁰C for different periods of time (between one and twelve hours) without any 
artificial atmosphere.  These degraded tablets were examined by FI-GR-SA-MS for 
quantity of artesunate remaining in the tablet.  Signals whose intensity increased in 
intensity with increased tablet degradation time were designated as possible artesunate 
degradation products.  These species were then tentatively identified using accurate mass 
measurements.  Figure 18 is the electrospray mass spectrum resulting from an artesunate 
tablet that has been heated in an oven for six hours.  There was no DDA added to the 
solution in this run, to simplify the spectrum and allow for possible identification of any 
degradation products that may be present.  As compared to Figure 15b, the most intense 
peaks in the mass spectrum of Figure 18 are degradation product adducts, as opposed to 




Figure 18: Mass spectrum of degraded artesunate, tablet extract without DDA addition.  




While the intensity of some peaks changed significantly over a period of six hours 
of heating, the intensity of other peaks remained somewhat constant.  The ion 
representative of dihydroartemisinin, for example, stayed relatively constant for the entire 
duration of the degradation experiment with only a slight increase as the artesunate was 
degrading more rapidly.  The trace of the intensity of the ion indicative of artesunate 
concentration decreased significantly after approximately eight hours of heating.  Dips in 
the artesunate trace could be indicative of tablets resulting from different blisterpacks 
containing different quantities of artesunate or, more likely, the dips in intensity seen at 
the one and four hour marks of time in the oven could be an artifact due to the changing 
sensitivity in the mass spectrometer over time.  A trace of the intensities of three 




Figure 19: A trace of the intensities of three ions versus the length of time each sample 
was degraded in the oven.  The intensities reported were an average of the intensity 
during the peak 30 seconds of the EIC trace for three FI-GR-SA-MS runs without the 




Figure 19 suggests that many ongoing, perhaps parallel, reactions occur while the 
tablet is being degraded.  The trace of the intensity of Product 1 appears to be somewhat 
stable until later stages of the degradation experiment, and it seems that the product is 
also able to bind to artesunate, perhaps during the electrospray process.  Once the tablet 
has been degraded for nine hours, the formation of Product 1 seems to increase 
significantly.  As the artesunate tablet was further degraded, a plethora of new peaks were 
observed in the mass spectrum.  While effort was put forth to examine every peak, it was 
not possible to identify all species present.  Because manufacturers do not fully disclose 
excipients used and because these excipients are most likely being degraded when 
exposed to high temperatures for extended periods of time, the possible structures are 
endless.  The species that could be identified by their accurate mass measurements in the 
degraded artesunate mass spectrum are shown in Table 2, on the next page.   
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C15H22O4Na 289.1416 289.1418 0.8197 [Product 1+Na]+ 
C15H24O5Na 307.1521 307.1522 0.2279 [Dihydroartemisinin+Na]+ 
C19H28O8Na 407.1682 407.1680 0.4593 [Artesunate+Na]+ 
C34H50O12Na 673.3200 673.3205 0.8050 [Artesunate+Product 1+Na]+ 





All accurate mass values and isotopic abundances of the proposed elemental 
formulas correspond very well with the theoretical values, suggesting correct 
identification of these compounds.  The [Artesunate+ Product2+ Na]+ ion had a 
significantly higher error than the other components identified in Table 2, however, this 
discrepancy can be attributed to the fact that this signal is nearing the edge of the 
calibrated m/z region. 
 While Product 1 was identified in the mass spectrum both individually and as a 
complex with artesunate, Product 2 was found uncomplexed in the mass spectrum.  It is 
possible that Product 2 did not ionize well by itself, or its affinity to artesunate was too 
strong.  The fact that these degradation products preferentially bind to artesunate was not 
surprising, as artesunate is often detected as a dimer at high concentrations.  For example, 
when artesunate tablets are analyzed by DART-MS, the artesunate ion is rarely seen 
intact, although the dimer is often detected.  It is possible that formation of these clusters 




Figure 20: Percent of API remaining after artesunate tablets have been degraded in the 
oven at ~100ºC for 0-12 hours.  Solid circles represent the values obtained using FI-GR-
SA-MS analysis, while the open circles represent data obtained using HPLC.  Error bars 
represent one standard deviation for the data set of 3 measurements.  
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 Figure 20 displays the percent of artesunate remaining in each tablet versus the 
amount of time the tablet was left to degrade in the oven.  FI-GR-SA-MS and HPLC 
were both used to analyze the artesunate content in these tablets.  The solid circles 
represent the values obtained with FI-GR-SA-MS, while the open circles represent values 
obtained by using HPLC.  Each sample was run in triplicate for each method and the 
error bars represent one standard deviation of the technical replicates.  As can be seen in 
Figure 20, the results of these two analytical techniques overlapped in all cases, 
demonstrating that the comparable results can be achieved using both FI-GR-SA-MS and 
HPLC, a widely accepted method of quantitation.  Figure 21 further compares the HPLC 
and FIA results.  A confidence level of 95% was used in calculations of the confidence 
interval for the line fitted to the HPLC data versus the FI-GR-SA-MS data.  Figure 21, 
indicates that the calculated confidence intervals encompass a slope of one and a y-
intercept of zero, verifying that these data statistically overlap with one another.  It should 
be noted that the data corresponding to the tablet degraded for eight hours was deemed a 




Figure 21: HPLC data versus FI-GR-SA-MS data with 95% confidence intervals added.  
Because the intervals include a slope of one and a y intercept of zero, the accuracy of the 




 The degradation experiment was repeated using 50 mg artesunate oral tablets 
produced by Guilin Pharmaceuticals (see Appendix A.3), a different brand than the ones 
previously used (Holley-Cotec Pharmaceuticals, Figure 20).  The degradation curves for 
these two brands of artesunate tablets were very dissimilar, with the tablets from Guilin 
Pharmaceuticals degrading approximately four times faster than the tablets from Holley-
Cotec Pharmaceuticals.  It is possible that a difference in excipients used contributed to 
the difference seen in the degradation curves.  It is also possible that the pressure used to 
press the tablets differed, resulting in a harder or softer tablet, for which the rate of heat 




Scheme 2: Proposed structures for artesunate degradation products. 
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 The degradation products that we propose are produced by thermal degradation, 
as the tablets were not exposed to sunlight, nor were they exposed to any high humidity 
levels besides the ambient humidity in the laboratory, approximately 9.2 grams per meter 
cubed.  The degradation products proposed in Scheme 2, above partially match what 
Haynes et al observed in their investigation of artesunate suppositories.  In Haynes’s 
study of artesunate suppository degradation products, the most abundant degradation 
product was dihydroartemisinin73.  In our experiments, dihydroartemisinin is consistently 
present for the entire duration of the artesunate degradation process, in a relatively 
consistent abundance.  We have not yet performed experiments to elucidate the details of 
the artesunate degradation pathways in tablets, specifically whether artesunate is 
degraded to dihydroartemisinin and subsequently dihydroartemisinin is degraded to the 
products seen in Scheme 2, or if the artesunate is degrading directly into the 
dihydroartemisinin and the products seen simultaneously. 
 A very interesting experiment to pursue with artesunate antimalarial tablets would 
be to synthesize these tablets with different known excipients and using different 
pressures to press these tablets.  The tablets could then be manually degraded and 
analyzed by the FI-GR-SA-MS method.  This would allow researchers to better 
understand which excipients and tablet hardness cause more rapid degradation to 
artesunate, allowing observations to be made concerning what properties of the excipients 









4.1 DART Screening of Poor Quality Medicines 
 Enormous effort is spent in determining the most efficacious antimalarials for 
country malaria programs, but it is essential that the quality of the drugs subsequently 
distributed is monitored and good quality of drug supply must be maintained. The drug 
screening methods presented here can be used to assure the quality of drugs, but many of 
these techniques are not available in the majority of the malarious world. Hence, there are 
few data to inform policy in situ or to rapidly intervene. Further research is needed to 
determine the extent of the drug quality problem, evaluations of appropriate methods for 
drug quality assessment, estimation of the impact of poor-quality medicines and the 
effectiveness of possible interventions must be evaluated.   
A stronger alliance with pharmaceutical companies is a crucial step to ensure the 
drug quality in these less developed regions.  Compliance of pharmaceutical companies 
with requests for genuine medicines to be analyzed by scientists would build a strong 
alliance.  Because analysts would have a genuine for comparison, this would allow 
verification as to whether drugs are genuine or poor quality and which subset of poor 
quality drugs collected pharmaceuticals may fit into.   
Enhanced regulation and quality assurance of the proliferating genuine 
manufacturers would help reduce the problematic presence of substandard drugs, while 
MRAs strengthening storage regulations would assist in decreasing the presence of 
degraded pharmaceuticals distributed to patients.  Better collaboration between academic 
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research, the pharmaceutical industry, medicines regulatory authorities and the law-
enforcement agencies will greatly help to ensure that the vulnerable are protected from 
poor-quality medicines.  
 
4.2 Internal Energy Deposition of DART-MS 
 Utilizing the “survival yield” method, the Eint distribution of a series of p-
substituted benzylpyridinium ions was compared between ESI and DART TOF MS. 
Although differences in some experimental settings were unavoidable to produce high 
quality data, ESI was the “softer” of the two ionization techniques with some overlap in 
energy distributions with DART. Thermal ion activation was a major contributor to Eint 
deposition in DART. Additionally, in-source CID in the first pumped region of the mass 
spectrometer contributed to DART Eint deposition as gas flow rates and set temperatures 
were increased. Although the work presented here improves our understanding of the 
fundamental desorption and ionization processes taking place when utilizing DART, 
more work in this area is still necessary.  In particular, the effect of ambient humidity, 
nitrogen gas as a source of metastables, and the contributions of ambient ion transport 
fluid dynamics to ion activation under other configurations are likely to be worthwhile 
endeavors for future investigation. 
 
4.3 Flow Injection Gradient Ratio Standard Addition Method for MS 
 The rapid method for quantification of active pharmaceutical ingredients 
presented here has the advantage of being much faster than traditional methods used for 
quantitative analysis of pharmaceuticals.  Because an isotopically labeled standard is not 
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required, this method is more economical than common methods used for quantification 
in mass spectrometry. Additionally, this new method also allows the user to detect 
degradation products, enables the distinction between degraded and substandard 
pharmaceuticals.  These types of poor quality medicines are a serious issue in developing 







Artesmisinin Combination Therapy Survey 
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‘Artesunate’ stated to 
be manufactured by 
‘Mediplantex 
358 Giai Phong Road 
– Hanoi- Viet Nam’ 
No hologram 
Reg. No.  
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be manufactured by 
‘Mekophar Chemical 
Pharmaceutical Joint-
Stock Co.’ and 
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‘NEROS 
PHARMACUETICA














B. Counterfeit dihydroartemisinin (DHA) collected in Kenya and Nigeria. All samples stated to contain 60mg 
DHA. All stated to be manufactured by ‘Jiaxing Nanhu Pharmaceutical Co. Ltd. Jiaxing City, under license of 
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C. Counterfeit halofantrine collected in West Africa and China. Tablets stated to contain 250mg 
halofantrine 
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D. Counterfeit co-formulated dihydroartemisinin-piperaquine collected in China, destined for Africa. 
Tablets stated to contain co-formulated dihydroartemisinin-piperaquine (40mg & 320mg). All stated to be 
manufactured by ‘Zheijiang Holley Nanhu Pharmaceutical Group Ltd Under license of HolleyPharm’ with 
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English text on 
packet edge (Fig 1E). 
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E. Counterfeit artemether-lumefantrine collected in Ghana and Cameroon. All tablets stated to contain co-
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F. Counterfeit co-formulated sulphamethopyrazine and pyrimethamine collected in Tanzania and Uganda. 
Tablets stated to contain co-formulated sulphamethopyrazine and pyrimethamine (500mg & 25mg). All 
stated to be manufactured by ‘Pharmacia Italia S.p. A. Ascoli Piceno under authority of Pfizer INC. N/Y.’ 
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* Genuine sample from manufacturer not available for comparison αActive 
Pharmaceutical Ingredient (API) detected by DESI-MS, βAPI verified by DART-MS, 
γAPI detected by FTIR and verified when necessary by HPLC-ESI-MS. A (abundant, > 
60%), C (common, 20-60%), M (minor, 5-20%), T (trace < 5%). Clay minerals are 
probably smectite and chlorite. HPLC-UV = high performance liquid chromatography 
with ultraviolet detection, FI-ESI-MS = flow injection electrospray ionization mass 
spectrometry, XRD = X-ray diffraction, XRF= X-ray fluorescence, FTIR = Fourier 
Transform Infra Red spectroscopy, HPLC-ESI-Ms = high performance liquid 
chromatography with electrospray ionisation and mass spectrometry detection, ACT = 
artemisinin-based combination therapy, GSK = GlaxoSmithKline, SB = SmithKline 
Beecham, LSHTM – HPLC analysis performed ny HK at London School of Hygiene and 
Tropical Medicine – see Ioset & Kaur (2009). 
1 Reported in Ioset & Kaur (2009)  Meta-alunogen is aluminium sulphate hydrate 








Below is a sample screenshot of the CODFIN database. This database contains 
information about each investigated sample, identified by a unique sample code. In the 
entry for each sample are links to documents containing a barcode, photos of the sample, 
and ASCII data, which may be used to plot spectral information (MS, Raman, NIR). 
 
	  
Figure 22: A snapshot of the CODFIN database with inlays of the barcode, picture, and 
MS data that is linked to the database. 
 
 Microsoft SharePoint Server is the program used to host the database.  A quad-
core computer was purchased and is maintained solely for the use of the database 
information.  This server allows for anyone to access the database, provided they have a 
valid username and password, from all over the world.  Users have the ability to update 
the database or upload new data.  All database information is kept in the documents 
portion of the SharePoint Server website and organized either by country where the 
LA 09-02
m/z














medicines were collected or a particular study name, if the location of medicine 
collection is no known.  Barcodes are generated based on the code name of each sample.  
The barcode also includes stated manufacturer, claimed active ingredients, and whether 
the medicine contains that claimed active ingredient based on MS screening of that 
medicine.  Barcodes are created using TBarcode, a software purchased for this particular 
task.  DataMatrix barcodes was the type of barcode used, as this type holds the most 
information.  If a user is unsure what medicine they are examining, in the open database 
excel sheet, a find function can be opened, then the barcode scanned with a 2D barcode 
scanner.  This allows the computer to immediately find all the gathered data on that 









Degradation Curve for Guilin Pharmaceuticals Artesunate Tablet 
Time in Oven (h)



















Figure 23: Percent of API remaining after artesunate tablets have been degraded in the 
oven at ~100ºC for 0-12 hours.  Analysis was performed using the FI-GR-SA-MS 
method.  Error bars represent one standard deviation for the data set of three 











Ring Lens: 5 V 
Orifice 1: 20 V 
Orifice 2: 25 V 
Peaks Voltage: 300 V 
Bias Voltage: 27 V 
Pusher Bias Voltage: -0.27 V 
Focus Voltage: -135 V 
Focus Lens Voltage: 1.0 V 
Quadrupole Lens Voltage: -5.0 V 
Right/Left Voltage: 13.7 V 
Top/Bottom Voltage: 3.7 V 
Reflectron: 917.7 V 
Detector Voltage: 2750 V 
DART Conditions: 
Temperature: 200⁰C 
Discharge gas and flow rate: Helium at 4 L/min 
Needle Voltage: 3600 V 
Discharge Electrode: 200 V 




Bruker MicroTOF Q: 
Scan Begin: 22 m/z 
Scan End: 1000 m/z 
Ion Polarity: Positive 
Set Nebulizer Gas: 0.0 Bar 
Set Dry Heater: 150⁰C 
Set Dry Gas: 2.0 L/min 
Set Capillary: 1500 V 
Set End Plate Offset: -500V 
Set Hexapole Storage: 41.0 V 
Set Hexapole Extraction: 32.0 V 
Set Lens 2: -4.0 V 
Set Lens 3: 35.0 V 
Set Lens 4: 28.0 V 
Set Lens 5: -27.0 V 
Set Lens 6: 23.0 V 
Set Collision Storage: 35.0 V 
Set Collision Extraction: 19.6 V 
Set Lens 7: 7.0 V 
Set Lens 8: -18.0 V 
Set Lens 9: 0.0 V 
Set Lens 10: -10.0 V 
Set Funnel 1 RF: 250.0 Vpp 
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Set Funnel 2 RF: 300.0 Vpp 
Set Hexapole RF: 300.00 Vpp 
Set Collision Cell RF: 250.0 Vpp 
Set Transfer Time: 77.0 µs 
Set Pre Pulse Storage Time: 1.0 µs 
Set Corrector Fill: 55.0 V 
Set Pulser Pull: 0.1 V 
Set Pulser Push: 804.0 V 
Set Reflector: 1800.0 V 
Set Flight Tube: 8600.0 V 
Set Corrector Extract: 683.0 V 
Set Detector TOF: 2007.2 V 
DART Conditions: 
Temperature: 200⁰C 
Discharge gas and flow rate: Helium at 1 L/min 
Needle Voltage: 3600 V 
Discharge Electrode: 150 V 






Mass Spectrometer Settings for IE Deposition of DART 
 
Ring Lens: 5 V 
Orifice 1: 20 V 
Orifice 2: 5 V 
Peaks Voltage: 300 V 
Bias Voltage: 27 V 
Pusher Bias Voltage: -0.27 V 
Focus Voltage: -135 V 
Focus Lens Voltage: 1.0 V 
Quadrupole Lens Voltage: -5.0 V 
Right/Left Voltage: 13.7 V 
Top/Bottom Voltage: 3.7 V 
Reflectron: 917.7 V 








Mass Spectrometer Settings for Flow Injection Gradient Ratio Standard Addition 
Method 
 
Source Type: ESI 
Focus: Not active 
Scan Begin: 150 m/z 
Scan End: 1000 m/z 
Ion Polarity: Positive 
Set Capillary: 4500 V 
Set End Plate Offset: -500 V 
Set Nebulizer: 1.0 Bar 
Set Dry Heater: 200⁰C 
Set Dry Gas: 5.0 L/min 
Set Hexapole Storage: 42.5 
Set Hexapole Extraction: 33.5 V 
Set Lens 2: -2.5 V 
Set Lens 3: 36.5 V 
Set Lens 4: 23.5 V 
Set Lens 5: -31.5 V 
Set Lens 6: 18.5 V 
Set Collision Storage: 35.0 V 
Set Collision Extraction: 19.6 V 
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Set Lens 7: 7.0 V 
Set Lens 8: -18.0 V 
Set Lens 9: 0.0 V 
Set Lens 10: -30.0 V 
Set Funnel 1 RF: 400.0 Vpp 
Set Funnel 2 RF: 400.0 Vpp 
Set Funnel 3 RF: 460.0 Vpp 
ISCID Energy: 0.0 V 
Set Collision Cell RF: 450.0 Vpp 
Set Transfer Time: 90.0 µs 
Set Pre Pulse Storage Time: 10.0 µs 
Set Corrector Fill: 55.0 V 
Set Pulser Pull: 0.1 V 
Set Pulser Push: 804.0 V 
Set Reflector: 1800.0 V 
Set Flight Tube: 8600.0 V 
Set Corrector Extract: 683.0 V 
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